The oncology therapy developer has filed for an IPO just two years after emerging from stealth to advance Harvard and Stanford research.
Centessa, formed earlier this year through a ten-way merger involving multiple spinouts, has completed a listing in the US.
The Lund research-based oat milk brand has floated in a $1.43bn IPO on the Nasdaq Global Select Market after pricing shares at $17.
SUNY Polytechnic University-backed Norsk Titanium has begun trading on Euronext Growth Oslo.
Yale's immunological disease treatment developer floated its shares below its initial price range in an IPO in the US.
Cambridge’s gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.
The stem cell-transplant technology developer, partly based on Stanford research, is going public through a reverse merger that will give it a $490m market capitalisation.
Talaris has raised $150m in an initial public offering almost two decades after being spun out of University of Louisville as Regenerx.